This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149 , a novel combination of an approved longacting 2-agonist , indacaterol ( Onbrez Breezhaler for COPD ) , and an approved inhaled corticosteroid , mometasone furoate ( MF ) , ( Asmanex Twisthaler for asthma ) , following multiple dose administration of QMF149 ( indacaterol acetate/MF ) 150/80 g and 150/320 g via the Breezhaler device in healthy Japanese and Caucasian subjects .